Quick answer
NMN and resveratrol are paired because of laboratory research: resveratrol was developed as an activator of sirtuins, enzymes that need NAD+, and NMN raises NAD+ in the blood. We found no trial in people that tested them together. Europe judged NMN safe up to 300 mg a day and caps resveratrol supplements at 150 mg.1,2,3,4
Key facts
- A meta-analysis of 12 trials found that NMN raised blood NAD+, while most of the health measures checked did not differ from placebo.2
- At least 70% of a resveratrol dose is absorbed, but only traces reach the blood unchanged.5
- Our NMN gives 500 mg a day and our Resveratrol label 600 mg of trans-resveratrol a day, both above Europe's figures.3,4
- Four weeks after the last dose of NMN, blood NAD+ was back at its starting level.6
Why they are sold as a pair
The pairing comes from laboratory and animal research on aging. Sirtuins are enzymes that need NAD+ to work. Resveratrol was developed as an activator of one of them, SIRT1, and NMN feeds the body's supply of NAD+, so the idea is that one supplies the fuel while the other flips the switch.1
That idea has not been tested in people. We found no trial that gave both, and the evidence for each one alone is thin: NMN reliably raises a blood marker, and resveratrol's one graded finding is small and from mixed groups of people.2,7
At least 70% of a 25 mg dose was absorbed, yet only trace amounts of unchanged resveratrol reached the blood; its sulfate and glucuronide forms reached levels up to about 20 times higher.5,8
What each has shown on its own
Neither finding below involves the other ingredient, and neither measures aging itself.
Raises NAD+ levels in the blood*2,3,9
Moderate evidence
A meta-analysis of 12 randomized trials (513 adults) found that NMN raised blood NAD+, and a 60-day trial in 80 healthy adults aged 40 to 65 found increases at 300, 600 and 900 mg a day. The trials were small and short, several were funded by NMN makers, all carried some risk of bias, and the same meta-analysis found that most health outcomes were no different from placebo.
Amount studied: 250 to 900 mg a day, for up to 12 weeks
May support normal blood vessel function*7,10
Early evidence
A 2022 meta-analysis of randomized trials found a small improvement in flow-mediated dilation, a test of how well an artery widens (about 1.4 percentage points); a 2026 umbrella review rated this as moderate-certainty evidence from 8 trials (603 people) that used 30 to 500 mg a day for 1 to 24 weeks. The trials enrolled mixed groups that included people under medical care, none used this product's 600 mg label dose, and the umbrella review saw weaker or less favorable results overall at 500 mg a day or more.
Amount studied: 30 to 500 mg a day for 1 to 24 weeks
Across 12 randomized trials, most of the health measures checked, including blood fats, did not differ from placebo.2
Exercise: single trials that point different ways
In 27 inactive men around 65 doing 8 weeks of high-intensity training, the gain in maximal oxygen uptake was 45% larger with placebo than with 250 mg of trans-resveratrol a day.11
In 48 amateur runners training for six weeks, breathing-threshold measures changed more than with placebo at 600 and 1,200 mg a day, while maximal oxygen uptake and peak power did not change.12
These are single trials in different groups, older inactive men and young amateur runners, so they do not show that one ingredient cancels the other. They do show that the two have not behaved alike when taken with training.11,12
When to take them
No study tested a schedule for the pair. The separate studies did this:
Trials have given NMN once a day before breakfast with water, or split into a morning and an evening dose.6,9
In a 12-week trial of 108 adults in their 70s, 250 mg was taken either before noon or between 6 pm and bedtime. Chair-stand times and drowsiness scores changed most in the evening NMN group, but the evening placebo group's drowsiness scores also changed, and the NMN maker funded the trial.13
Resveratrol reaches its highest level in the blood about 30 minutes to 2 hours after a dose.14,15
At 2,000 mg twice a day, a high-fat breakfast lowered blood levels by about 45% compared with a standard breakfast.16
So the trials do not settle a best time. NMN has been taken before breakfast and in the evening, and with resveratrol, the timing question the studies answer is about meals rather than the clock.6,13,15
How much of each
| NMN | Resveratrol | |
|---|---|---|
| Most common amount in trials | 250 mg a day | 30 to 500 mg a day in the blood vessel trials |
| Range tested | 250 to 2,000 mg a day, for up to 24 weeks | Up to 5 g a day for 29 days in healthy volunteers |
| Europe's figure | Judged safe up to 300 mg a day | Capped at 150 mg a day of synthetic trans-resveratrol |
| Our product, per day | 500 mg | 600 mg of trans-resveratrol at two capsules |
No source sets an amount of resveratrol to go with NMN; the figures above are each ingredient's own. In the blood vessel trials, results were weaker at 500 mg of resveratrol a day or more, so a larger amount did not do better there.7
What's in ours
What’s in ours
- NMN: β-Nicotinamide Mononucleotide, 500 mg per serving, from the label
Both of our labels sit above Europe's figures: 500 mg of NMN against the 300 mg Europe assessed, and 600 mg of trans-resveratrol a day at two capsules against the 150 mg cap. One resveratrol capsule, 300 mg, is closer to the amounts studied.3,4,7
Side effects, medicines and who should ask first
Use for longer than 24 weeks has not been studied in trials, so long-term effects are unknown.3,17
Europe counts NMN as a source of nicotinamide, so it adds to the vitamin B3 in multivitamins and in niacin, nicotinamide or nicotinamide riboside supplements.3
In 11 healthy adults taking 250 mg each morning for 12 weeks, insulin measured after lunch rose, by very different amounts from person to person.18
In a 2026 review, trials lasting 12 weeks or more raised alkaline phosphatase, an enzyme measured in routine blood tests, an effect rated high certainty.7
Ask your pharmacist or doctor first
NIH's LiverTox database lists a possible interaction between resveratrol and anticoagulant blood thinners. The warfarin label asks for more frequent INR checks whenever a botanical product is started or stopped, and MedlinePlus says some supplements may raise the risk of bleeding with warfarin.19,20,21
Expected from how the two work, not shown in studies
Nobody has measured what the two do together to blood tests or to medicines. Each has been studied for 24 weeks at most, so for the pair, long-term effects are a blank.7,17
- Ask your doctor or pharmacist first if you take any prescription medicine, including medicines for blood sugar4,18
- Ask first if you take a blood thinner or have a bleeding disorder19
- Ask first if you already take niacin, nicotinamide or nicotinamide riboside3
- Ask first if you take estrogen, have a hormone-sensitive condition or have liver disease19
- Ask first if you are pregnant or nursing, or under 18: Europe's NMN assessment does not cover pregnancy or breastfeeding3
Questions people ask
Does resveratrol need to be taken with fat?
The studies we read do not back that up. After a high-fat meal, a 400 mg dose peaked later but the total absorbed did not change in a relevant way, and at 2,000 mg twice a day a high-fat breakfast cut blood levels by about 45%.15,16
See what we make
Every product shows its whole label and what its lab report covers. The store opens soon.
Sources
- Imai S. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res. 2010;62(1):42-47. Opened 2026-10-07.
- Zhang J, Poon ET, Wong SH. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Crit Rev Food Sci Nutr. 2025;65(22):4382-4400. Opened 2026-10-01.
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Bohn T, Cámara M, et al. Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. EFSA J. 2026;24(5):e10007. Opened 2026-10-01.
- European Commission. Commission Implementing Decision (EU) 2016/1190 of 19 July 2016 authorising the placing on the market of trans-resveratrol as a novel food ingredient under Regulation (EC) No 258/97. Official Journal of the European Union, L 196, 21.7.2016, p. 53. Opened 2026-10-07.
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32(12):1377-1382. Opened 2026-10-07.
- Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022;9:868640. Opened 2026-10-07.
- Sun JN, Yang R, Fang L, et al. Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutr J. 2026;25(1):63. Opened 2026-10-01.
- Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003-9011. Opened 2026-10-01.
- Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience. 2023;45(1):29-43. Opened 2026-10-01.
- Mohammadipoor N, Shafiee F, Rostami A, et al. Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(9):3529-3539. Opened 2026-10-01.
- Gliemann L, Schmidt JF, Olesen J, et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol. 2013;591(20):5047-5059. Opened 2026-10-01.
- Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. Opened 2026-10-01.
- Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022;14(4):755. Opened 2026-10-07.
- Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53 Suppl 1:S7-S15. Opened 2026-10-07.
- Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46(11):564-570. Opened 2026-10-07.
- la Porte C, Voduc N, Zhang G, et al. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49(7):449-454. Opened 2026-10-07.
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. Opened 2026-10-07.
- Yamane T, Imai M, Bamba T, Uchiyama S. Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects. Clin Nutr ESPEN. 2023;56:83-86. Opened 2026-10-07.
- Resveratrol. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Updated November 30, 2024. Opened 2026-10-01.
- Warfarin sodium tablets: prescribing information and Medication Guide (Teva Pharmaceuticals USA). DailyMed, U.S. National Library of Medicine. Published June 23, 2025. Opened 2026-10-07.
- Warfarin. MedlinePlus Drug Information, U.S. National Library of Medicine. Last revised March 15, 2026. Opened 2026-10-07.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This page is information, not medical advice. Talk to your doctor or pharmacist about your own situation.